利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.015 秒)

    Indoleamine 2,3-dioxygenase based immunotherapy
    2.
    发明授权
    Indoleamine 2,3-dioxygenase based immunotherapy 有权

    公开(公告)号：US10258678B2

    公开(公告)日：2019-04-16

    申请号：US15231075

    申请日：2016-08-08

    申请人： IO Biotech ApS

    发明人： Mads Hald Andersen ,  Per Thor Straten

    IPC分类号： A61K39/395 ,  A61K39/00 ,  A61K38/19 ,  A61K38/20 ,  A61K45/06 ,  C12N9/02

    摘要： The present invention relates to the field of prophylaxis and therapy of cancer. In particular there is provided a protein Indoleamine 2,3-dioxygenase (IDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of IDO or peptides derived here from or IDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to IDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above.The use of IDO and immunogenic peptide fragments hereof in cancer and infection treatment, diagnosis and prognosis is also provided.

    ARGINASE1 POLYPEPTIDES
    4.
    发明申请
    ARGINASE1 POLYPEPTIDES 有权

    公开(公告)号：US20220031818A1

    公开(公告)日：2022-02-03

    申请号：US17278838

    申请日：2019-09-24

    申请人： IO BIOTECH APS

    发明人： Mads Hald Andersen

    IPC分类号： A61K38/50 ,  C12N9/78 ,  A61K45/06 ,  A61P35/00 ,  A61K39/00

    摘要： The present invention relates to novel polypeptides, which are derived from Arginase 1. The invention also relates to polynucleotides encoding the polypeptides. The invention also relates to compositions comprising the polypeptides and polynucleotides. The invention also concerns uses of the polypeptides, polynucleotides, and compositions.

    PDL2 compounds
    5.
    发明授权
    PDL2 compounds 有权

    公开(公告)号：US11447537B2

    公开(公告)日：2022-09-20

    申请号：US16911996

    申请日：2020-06-25

    申请人： IO Biotech ApS

    发明人： Mads Hald Andersen

    IPC分类号： C07K14/705 ,  A61P35/00 ,  A61K39/39 ,  A61K39/00 ,  A61K38/00 ,  A61K45/06

    摘要： The present invention relates to a peptide compound of PDL2 selected from a peptide fragment, a functional homologue, and a functional analogue, as well as to a nucleic acid, such as DNA or RNA, encoding the peptide compound, a vector, such as a virus vector, and a host cell, such as mammalian cell, comprising the vector. The peptide compound, nucleic acid, vector and host cell of the present invention are in particular, useful for the treatment or prevention of a cancer characterized by expression of PDL2.

    Indoleamine 2,3-dioxygenase based immunotherapy
    6.
    发明授权
    Indoleamine 2,3-dioxygenase based immunotherapy 有权

    公开(公告)号：US11324813B2

    公开(公告)日：2022-05-10

    申请号：US16261114

    申请日：2019-01-29

    申请人： IO Biotech ApS

    发明人： Mads Hald Andersen ,  Per Thor Straten

    IPC分类号： A61K39/395 ,  A61K39/00 ,  A61K38/19 ,  A61K38/20 ,  A61K45/06 ,  C12N9/02

    摘要： The present invention relates to the field of prophylaxis and therapy of cancer. In particular there is provided a protein Indoleamine 2,3-dioxygenase (IDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of IDO or peptides derived here from or IDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to IDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above.
    The use of IDO and immunogenic peptide fragments hereof in cancer and infection treatment, diagnosis and prognosis is also provided.